Global Lactase Market Trends and Insights
Growing Prevalence of Lactose Intolerance
The lactase market has a broad demand base because lactose malabsorption affects a large share of the global population, influencing both day-to-day plant management and longer-term product planning. The U.S. National Library of Medicine states that lactose intolerance is common and occurs when the small intestine does not make enough lactase, reinforcing its relevance to commercial dairy formulation and production planning and affecting how suppliers support dairy customers with technical and commercial guidance. Nearly 70% of adults globally have genetic lactase non-persistence, particularly in Asia, Africa, and Latin America, making them unable to digest conventional dairy products without discomfort, according to the MedlinePlus data . Better diagnostic access can shift consumers from avoiding dairy to choosing lactose-reduced dairy products, and this is relevant when processors plan sourcing, production, and product placement. This creates an opportunity for processors to retain dairy consumption among people who experience symptoms after consuming conventional milk products, remaining important across formulation, plant operations, and customer delivery. The lactase market therefore benefits when health guidance, retail availability, and consumer income support lactose-reduced choices.Enzyme-Immobilization Technologies Reducing Production Costs
Immobilized lactase can lower the cost of lactose hydrolysis because the enzyme can be used across more than one processing cycle, with the commercial effect depending on reliable execution across the dairy value chain. A 2025 Scientific Reports study found that an immobilized lactase system retained activity through at least 8 reuse cycles and remained stable for 90 days at 4°C, while also shaping choices made by procurement and product development teams. The study also reported 50% lactose hydrolysis within the first hour in 3% fat milk, especially where product consistency and operating discipline are essential. Separate 2025 research reported 69% activity retention after 12 sequential reuse cycles for recombinant BgaC lactase immobilized in alginate-gelatin beads, reinforcing its relevance to commercial dairy formulation and production planning, influencing both day-to-day plant management and longer-term product planning. These results support the case for reuse-based systems in dairy plants that can operate fixed-bed or comparable processing equipment, affecting how suppliers support dairy customers with technical and commercial guidance. The lactase market may gain new mid-scale users as these systems move from laboratory studies into validated production settings.Volatility in Dairy Supply Affecting Enzyme off-Take
Lactase use is linked directly to the volume of milk processed in dairy facilities, remaining important across formulation, plant operations, and customer delivery. When processors reduce milk intake, lactase procurement can fall because dosage is tied to processing throughput, with the commercial effect depending on reliable execution across the dairy value chain. This exposure is relevant in places affected by weather variability, herd reductions, or weak farm-gate prices, while also shaping choices made by procurement and product development teams. Multi-year supply agreements do not fully protect enzyme suppliers against lower production volumes, especially where product consistency and operating discipline are essential. Liquid enzyme inventory can also add refrigerated storage costs when demand is delayed, influencing both day-to-day plant management and longer-term product planning.Other drivers and restraints analyzed in the report include:
- Rising Demand for Clean-Label Enzymes
- Low-Sugar Positioning Enabled by Lactase
- Regulatory Hurdles for GMO-Derived Recombinant Lactase
Segment Analysis
Liquid lactase held 44.23% of the form segment in 2025, while also shaping choices made by procurement and product development teams. It remains widely used in high-throughput plants where continuous-flow dosing and cleaning-in-place compatibility are important, especially where product consistency and operating discipline are essential. Precise volumetric control also supports consistent hydrolysis across large production runs, influencing both day-to-day plant management and longer-term product planning. Liquid preparations fit established operating procedures at many large dairy facilities, affecting how suppliers support dairy customers with technical and commercial guidance.Dry/powder lactase is forecast to expand at a 7.48% CAGR during 2026-2031. It offers ambient-temperature storage and reduces the cost and complexity of refrigerated shipping, and this is relevant when processors plan sourcing, production, and product placement. These features are relevant for smaller processors and co-manufacturers that do not have inline injection equipment, remaining important across formulation, plant operations, and customer delivery. The form also supports batch dosing for new lactose-free product programs, with the commercial effect depending on reliable execution across the dairy value chain.
Complete Report Scope:
- Form
- Liquid
- Dry/Powder
- Granular/Immobilise
- Source
- Yeast
- Fungi
- Bacteria
- Application
- Dairy Processing
- Cheese
- Yogurt
- Ice-Cream
- Other Dairy Processing
- Dietary Supplements and Pharmaceuticals
- Other Applications
- Dairy Processing
- Geography
- North America
- United States
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- United Kingdom
- France
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Rest of Asia-Pacific
- South America
- Middle East and Africa
- North America
Geography Analysis
North America held 34.05% of the global lactase market in 2025, while also shaping choices made by procurement and product development teams. Mature lactose-free retail distribution, high dairy consumption, and established enzyme-capable processors support regional demand, especially where product consistency and operating discipline are essential. The United States accounts for much of this activity because lactose-free dairy is available across mainstream retail channels, influencing both day-to-day plant management and longer-term product planning. Private-label programs can extend category access beyond premium branded products, affecting how suppliers support dairy customers with technical and commercial guidance.Europe is the second-largest regional market, which matters as product teams align consumer needs with routine manufacturing decisions. Germany, France, and the United Kingdom are important demand centers for products supported by clean-label and non-GMO positioning, and this is relevant when processors plan sourcing, production, and product placement. Regulatory documentation under the European food enzyme framework reinforces the value of well-characterized enzyme sources, remaining important across formulation, plant operations, and customer delivery. South America and the Middle East and Africa hold smaller shares of the lactase market, with the commercial effect depending on reliable execution across the dairy value chain.
Asia-Pacific is forecast to grow at a 7.89% CAGR through 2031, while also shaping choices made by procurement and product development teams. The region has a large population with low genetic lactase persistence, which creates a broad potential demand base for lactose-treated dairy, especially where product consistency and operating discipline are essential. The opportunity depends on consumer awareness, organized dairy retail, and reliable access to food-grade enzymes, influencing both day-to-day plant management and longer-term product planning. India and China are important volume opportunities as urban consumers seek dairy products that better suit digestive needs, affecting how suppliers support dairy customers with technical and commercial guidance.
List of Companies Covered in this Report:
- DSM-Firmenich
- Novozymes A/S
- Kerry Group plc
- International Flavors and Fragrances Inc.
- Advanced Enzyme Technologies Ltd.
- Amano Enzyme Inc.
- Merck KGaA (Sigma-Aldrich)
- Infinita Biotech Pvt Ltd
- Gk Biochemical Corporation
- Biocatalysts Ltd.
- SternEnzym GmbH
- Enzyme Development Corp.
- Creative Enzymes
- Bioven Ingredients
- Shriji exbiz Pvt. Ltd.
- Biofermen Private Limited
- AB Enzymes
- Anthem Biosciences
- Optiferm GmbH
- Lactalis Ingredients
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- DSM-Firmenich
- Novozymes A/S
- Kerry Group plc
- International Flavors and Fragrances Inc.
- Advanced Enzyme Technologies Ltd.
- Amano Enzyme Inc.
- Merck KGaA (Sigma-Aldrich)
- Infinita Biotech Pvt Ltd
- Gk Biochemical Corporation
- Biocatalysts Ltd.
- SternEnzym GmbH
- Enzyme Development Corp.
- Creative Enzymes
- Bioven Ingredients
- Shriji exbiz Pvt. Ltd.
- Biofermen Private Limited
- AB Enzymes
- Anthem Biosciences
- Optiferm GmbH
- Lactalis Ingredients

